Molecular structure of Afatinib, CAS Number: 439081-18-2
Afatinib (CAS 439081-18-2)
See product citations (13)
Alternate Names:
BIBW 2992
Application:
Afatinib is an irreversible and potent EGFR/Neu inhibitor, inhibits EGFR phosphorylation.
CAS Number:
439081-18-2
Purity:
>99%
Molecular Weight:
485.94
Molecular Formula:
C24H25ClFN5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Afatinib is a chemical compound that serves as an important research tool in studying signal transduction pathways related to the epidermal growth factor receptor (EGFR) family, which includes HER2 and HER4. It is particularly noted for its irreversible inhibition of these receptor tyrosine kinases. As such, afatinib is employed in the investigation of the molecular mechanisms involved in cell proliferation and differentiation, as well as angiogenesis. It helps to elucidate the complex network of intracellular signaling cascades and their implications in various biological processes. Furthermore, afatinib is frequently used in the study of mechanisms contributing to cellular resistance against tyrosine kinase inhibitors, allowing researchers to explore new strategies to counteract this resistance in different cellular contexts.
Afatinib (CAS 439081-18-2) References
- Afatinib, a lung cancer inhibitor of ErbB family. | de Antonellis, P. 2014. Naunyn Schmiedebergs Arch Pharmacol. 387: 503-4. PMID: 24728512
- Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience. | Ezeife, DA., et al. 2018. Curr Oncol. 25: e385-e390. PMID: 30464688
- Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. | Vengoji, R., et al. 2019. J Exp Clin Cancer Res. 38: 266. PMID: 31215502
- Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy. | Elbatanony, RS., et al. 2021. Drug Deliv Transl Res. 11: 927-943. PMID: 32557351
- Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. | Cadranel, J., et al. 2021. Oncologist. 26: 7-16. PMID: 32852072
- A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. | Ito, K., et al. 2021. ESMO Open. 6: 100115. PMID: 33984681
- Afatinib in the treatment of brain metastases of lung cancer with one rare EGFR mutation: a two-case report. | Sun, L., et al. 2022. Anticancer Drugs. 33: 112-118. PMID: 34261910
- Afatinib induces pro-survival autophagy and increases sensitivity to apoptosis in stem-like HNSCC cells. | Liu, X., et al. 2021. Cell Death Dis. 12: 728. PMID: 34294686
- Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. | Li, T., et al. 2021. Thorac Cancer. 12: 2924-2932. PMID: 34549528
- GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib. | Chen, LY., et al. 2022. Acta Pharmacol Sin. 43: 1534-1543. PMID: 34552215
- Determination of Afatinib in Human Plasma by 2-Dimensional Liquid Chromatography. | Wang, Y., et al. 2022. Pharmacology. 107: 290-297. PMID: 35086096
- Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. | Kwok, WC., et al. 2022. Thorac Cancer. 13: 2057-2063. PMID: 35668712
- Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders. | Lin, PH., et al. 2022. J Formos Med Assoc. 121: 2538-2547. PMID: 35752529
- The Pan-ErbB tyrosine kinase inhibitor afatinib inhibits multiple steps of the mammarenavirus life cycle. | Mizuma, K., et al. 2022. Virology. 576: 83-95. PMID: 36183499
Inhibitor of:
9330159F19Rik, C5orf34_4833420G17Rik, CCT B, CLU1, Dist1, dsg1γ, EB2, EFR3A, EGFR, Epigen, Epiregulin, ETL, FAM75C2, GRHPR, Lung Carcinoma, NET-4, Olfr157, Olfr541, Olfr547, Olr1063, Olr1235, Olr1320, Olr1350, Olr375, Olr768, Olr83, Olr943, Olr962, OTTMUSG00000010673, Ppp2r3d, SPINK12, SS18L2, TOB1, Trav2, TREM-2c, VG5Q, Vmn1r57, Vmn2r115, VSIG10L, and ZNF57.Activator of:
BTC, ErbB-4, KRTAP2, and Neu.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Afatinib, 5 mg | sc-364398 | 5 mg | $112.00 | |||
Afatinib, 10 mg | sc-364398A | 10 mg | $194.00 |